Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Crinetics Pharmaceuticals Inc ( NASDAQ:CRNX ) has submitted its first NDA for paltusotine, a next-generation therapy for acromegaly, and anticipates FDA filing notification in December. The company is preparing for the anticipated launch of paltusotine by building commercial capabilities and engaging with payers for formulary placement. Crinetics Pharmaceuticals Inc ( NASDAQ:CRNX ) has a strong financial position with approximately $1.4 billion in cash and investments, projected to fund operations into 2029. The company is advancing a robust pipeline with multiple candidates, including CRN 9,682, a novel nonpeptide drug conjugate for cancer treatment. Positive results from a phase two study for carcinoid syndrome were reported, with plans to start a phase three trial on schedule. There were no revenues for the quarter ended September 30, 2024, compared to $0.3 million for the same period in 2023. Research and development expenses increased to $61.9 million for the quarter
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor ConferencesGlobeNewswire
- UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual MeetingGlobeNewswire
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Citigroup Inc. from $70.00 to $74.00. They now have a "buy" rating on the stock.MarketBeat
- Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
CRNX
Earnings
- 11/12/24 - Miss
CRNX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- CRNX's page on the SEC website